Loading page…

Abbott India Limited (ABBOTINDIA) · mywealthgrid

About

Abbott India Limited operates in pharmaceuticals within India's healthcare sector, with quarterly standalone revenues around ₹1,070 Cr and market cap of ₹57,367 Cr. The company delivers strong operating margins (27.31%) and ROE (34.46%), positioning it as a profitable mid-cap pharma player with consistent cash generation.

Face value: ₹10

Market cap

₹56,901 Cr

P/E

82.4×

P/B

11.9×

Dividend yield

4.2%

ROE

34.5%

ROCE

44.1%

Debt / equity

—

OPM

27.3%

EPS (TTM)

₹325.0

Book value

₹2,246.7

52-week high

₹30,255.0

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Steep valuation at PE 83.06 leaves minimal margin for error; verify whether earnings growth can justify the premium
Revenue flat at ~₹1,050–₹1,095 Cr/quarter for 18+ months signals growth stagnation; determine whether product mix, market share, or sector conditions are constraining growth
Net profit declined 15% in Mar 2021 (₹152.47 Cr vs. ₹180+ Cr prior quarters) despite flat revenue; verify whether this is temporary or structural
Very high promoter holding (74.99%) and minimal public float (15.85%) create illiquidity; verify if this reflects governance concerns or market positioning

Generated analysis · source review pending

Growth drivers

Operating margin expanded from 14.4% (Mar 2020) to 27.31% current; if this improvement is sustainable, it creates capacity for growth investment—verify what drove the expansion
ROE of 34.46% indicates capital efficiency; if reinvested earnings achieve similar returns, growth compounds—verify capital allocation strategy and available growth opportunities
Stable quarterly revenue of ~₹1,070 Cr provides a platform for expansion; pharma sector in India typically expands with healthcare spend—verify Abbott's market share in high-growth therapeutic segments vs. mature/generic categories

Generated analysis · source review pending

₹26,840.0-9.8%1Y

Beta

0.46

Damps index moves

Volatility (1y)

20.2%

Annualised, daily returns

RSI (14)

Neither overbought nor oversold

Rel. strength (1y)

-19.9%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Strong return on equity of 35% (3-yr avg)
+High return on capital employed of 44.9%
+Healthy operating margin of 27.3%
+Profit CAGR of 17.6% over the last 5 years
+Comfortable interest coverage of 84.2×
+Dividend yield of 4.2%
+High promoter holding of 75% with no pledge

Cons

−Modest revenue growth of 10% a year over the last 5 years
−Expensive at 82.4× trailing earnings
−Trading at 11.9× book value

Research score

Structured signal from quality, growth, valuation and momentum.

47/100

Business quality

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 150 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET NIFTY HEALTHCARE INDEX

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,628	2,939	3,316	3,679	4,093	4,310	4,913	5,349	5,849	6,409	6,929
COGS	-1,508	-1,712	-1,905	-2,089	-2,316	2,391	2,657	2,975	3,221	3,497	3,693
Gross profit	—	—	—	—	—	1,919	2,256	2,374	2,628	2,912	3,236
	3,770	4,253	4,687	5,162	5,652	998	1,174	1,168	1,175	1,218	1,344
Operating profit (EBITDA)	367	397	533	605	756	921	1,082	1,206	1,453	1,695	1,892
OPM %	14%	13.5%	16.1%	16.4%	18.5%	21.4%	22%	22.5%	24.8%	26.4%	27.3%
Depreciation	14	16	16	17	60	58	66	70	71	72	76
Interest	1	2	4	2	9	18	19	16	12	11	25
	50	58	109	113	114	81	83	154	248	276	288
Profit before tax	402	436	622	699	803	926	1,080	1,274	1,618	1,887	2,079
Tax	142	160	220	249	210	235	281	324	417	473	527
Tax %	35.4%	36.6%	35.4%	35.6%	26.1%	25.4%	26%	25.5%	25.8%	25%	25.4%
	260	277	401	450	593	691	799	949	1,201	1,414	1,552
PAT margin %	9.9%	9.4%	12.1%	12.2%	14.5%	16%	16.3%	17.8%	20.5%	22.1%	22.4%
EPS (₹)	122.2	130.2	188.8	211.9	279	325	375.9	446.8	—	665.6	—
EPS adjusted (₹)	122.2	—	188.8	211.9	279	325	375.9	446.8	565.3	665.6	730.4
	28.6%	30.7%	29.1%	30.7%	89.6%	84.6%	73.2%	72.7%	—	71.4%	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	21	21	21	21	21	21	21	21	21	21
Reserves	1,086	1,672	1,987	2,410	2,581	2,799	3,167	3,678	4,212	4,753
	—	—	—	—	0	0	0	0	0	—
	516	723	932	1,115	1,238	1,404	1,367	1,495	1,684	1,728
Total equity & liabilities	1,624	2,416	2,941	3,547	3,840	4,224	4,556	5,193	5,917	6,502
	108	81	105	101	104	132	138	154	140	166
CWIP	2	2	1	2	1	1	4	10	18	6
Investments	—	—	—	—	0	0	0	0	0	—
	1,514	2,333	2,835	3,444	3,735	4,092	4,414	5,030	5,759	6,330
Total assets	1,624	2,416	2,941	3,547	3,840	4,224	4,556	5,193	5,917	6,502

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	44.5%	45.9%	44.4%	44.9%	45.4%	46.7%
EBITDA margin %	16.4%	18.5%	21.4%	22%	22.5%	24.8%	26.4%	27.3%
EBIT margin %	16%	17%	20%	20.7%	21.2%	23.6%	25.3%	26.2%
PAT margin %	12.2%	14.5%	16%	16.3%	17.8%	20.5%	22.1%	22.4%
Working capital
Receivable days	27	28	21	21	22	20	22	19
Inventory days	72	58	110	94	80	70	92	94
Payable days	—	—	116	122	109	114	110	2
NWC days	—	—	14	-6	-8	-24	3	110
Leverage
Current ratio	3.22	3.6	3.41	3.2	2.51	2.42	3.37	2.55
Debt to EBITDA	—	—	0	0	0	0	0	—
Debt to equity	—	—	0	0	0	0	0	—
Interest coverage	310.2	95.1	51.7	57.5	80.7	130.9	166.1	84.2
Asset turnover	1.25	1.15	1.12	1.16	1.17	1.13	1.08	1.07
Return ratios
Return on assets %	15.3%	16.7%	18%	18.9%	20.8%	23.1%	23.9%	23.9%
Return on capital employed %	36.6%	34.2%	34.6%	37.7%	40.5%	45.3%	45.4%	44.1%
Return on equity %	22.4%	24.4%	26.5%	28.3%	29.8%	32.5%	33.4%	32.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%
	0.18%	0.18%	0.18%	0.18%	0.16%	0.16%	0.16%	0.16%	0.16%	0.18%	0.26%	0.38%
	8.83%	8.74%	8.91%	8.81%	8.99%	9.01%	8.92%	9.19%	9.11%	9%	8.93%	8.78%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	16%	16.09%	15.92%	16.02%	15.86%	15.84%	15.93%	15.66%	15.74%	15.83%	15.82%	15.85%
No. of shareholders	—	—	—	—	—	—	—	—	71,199	75,801	75,866	78,320

Promoter holding up 0 percentage points since Sep 2023.

Mr. Munir ShaikhNon-Executive - Non Independent Director-Chairperson
Mr. Kartik RajendranExecutive Director-MD
Mr. Vivek MohanNon-Executive - Non Independent Director
Mr. Sudarshan JainNon-Executive - Independent Director
Ms. Shalini KamathNon-Executive - Independent Director
Mr. Neeraj JainNon-Executive - Independent Director
Mr. Kaiyomarz MarfatiaNon-Executive - Non Independent Director
Mr. James WennerNon-Executive - Non Independent Director
Mr. Darshan GadaNon-Executive - Non Independent Director
Ms. Maithilee MistryChief Financial Officer
Ms. Sangeeta ShettyCompany Secretary & Compliance Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 14 fund houses

Held by these funds

5.46%

of the company's equity

All mutual funds

7.44%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

87 schemes · 14 fund houses

		Shares
Large and Midcap Fund	SBI Mutual Fund	3.08 L	796.18	1.88%	1.453%	-0
Multi Cap FundNEW	Nippon India Mutual Fund	1.47 L	379.2	0.67%	0.692%	—
Midcap Fund	Axis Mutual Fund	1.37 L	353.07	1%	0.644%	-26,262
PHARMA FUND	Nippon India Mutual Fund	78,126	201.96	2.13%	0.369%	+3,324
Healthcare FundNEW	ICICI Prudential Mutual Fund	64,361	166.37	2.38%	0.304%	—
MID CAP FUND	Tata Mutual Fund	50,000	129.25	2.07%	0.236%	+6,589
LARGE & MID CAP FUND	Tata Mutual Fund	40,000	103.4	1.35%	0.189%	+8,326
INDIA PHARMA & HEALTHCARE FUND	Tata Mutual Fund	32,924	85.11	5.44%	0.155%	+1,693

1–8 of 87

1 / 11

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

26

Final dividend24 Jul 2026 · ex-date₹525
Special dividend24 Jul 2026 · ex-date₹131
Final dividend25 Jul 2025 · ex-date₹475
Final dividend19 Jul 2024 · ex-date₹410
Special dividend21 Jul 2023 · ex-date₹145
Final dividend21 Jul 2023 · ex-date₹180
Final dividend2 Aug 2022 · ex-date₹145
Special dividend2 Aug 2022 · ex-date₹130
Special dividend19 Jul 2021 · ex-date₹155
Final dividend19 Jul 2021 · ex-date₹120
Final dividend28 Aug 2020 · ex-date₹107
Special dividend28 Aug 2020 · ex-date₹143
Final dividend13 Aug 2019 · ex-date₹50
Special dividend13 Aug 2019 · ex-date₹15
Final dividend10 Jul 2018 · ex-date₹50
Special dividend10 Jul 2018 · ex-date₹5
Final dividend10 Jul 2017 · ex-date₹40
Final dividend8 Jul 2016 · ex-date₹35
Final dividend22 Jul 2015 · ex-date₹31
Final dividend23 Jul 2014 · ex-date₹23
Final dividend16 Apr 2013 · ex-date₹17
Final dividend4 May 2012 · ex-date₹17
Final dividend19 Apr 2011 · ex-date₹17
Dividend dividend3 Mar 2010 · ex-date₹17
Dividend dividend9 Mar 2009 · ex-date₹14
Dividend dividend28 Mar 2008 · ex-date₹17.5

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

68 announcementsExport CSV

11 May 2026, 10:12 pmResult

Audited Financial Results For The Quarter And Year Ended March 31, 2026

Financial Results PDF

Loading announcements…

Date	Category	Subject	Filing
11 May 2026, 10:12 pm	Result Financial Results	Audited Financial Results For The Quarter And Year Ended March 31, 2026	PDF
11 May 2026, 10:04 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting	PDF
30 Apr 2026, 11:44 am	Board Meeting	Board Meeting Intimation for Considering Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, Along With The Audit Report Of The Statutory Auditors Thereon And To Recommend Final Dividend For The Financial Year Ended March 31, 2026.	PDF
30 Apr 2026, 11:35 am	Others Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A	Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A	PDF
22 Apr 2026, 12:32 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
22 Apr 2026, 12:29 pm	Others Outcome without intimation	Board Meeting Outcome for Outcome Of Board Meeting	PDF
8 Apr 2026, 4:08 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF
3 Apr 2026, 4:08 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

₹ Cr	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	251	153	499	626	727	948	893	1,213	1,012	1,319
	-80	-215	-257	-401	-72	-396	-148	-416	182	-371
	-80	-102	-143	-217	-582	-637	-639	-745	-925	-1,066
Net cash flow	91	-165	99	8	73	-86	107	52	269	-118
Free cash flow	—	153	499	626	703	904	859	1,164	959	1,319
CFO / Operating profit %	68.6%	28.7%	82.5%	82.8%	78.9%	87.6%	74.1%	83.5%	59.7%	69.7%

Abbott India Limited

Abbott India Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

26

1

Announcements

26

1

Not in the F&O segment

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Abbott India Limited

Abbott India Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

Dividends26

Board meetings1

Announcements

Dividends26

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Quarterly record

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

26

1

26

1